Loading news...
Absolute Software Co. (ABT.TO) (TSE: ABT - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of C$0.00 and traded as high as C$20.37. Absolute Software Co. (ABT.TO) shares last traded at C$20.37, with a volume of 421 shares changing hands. Absolute
Abbott (ABT) closed at $114.12 in the latest trading session, marking a -1.92% move from the prior day.
Banco Santander S.A. reduced its holdings in Abbott Laboratories (NYSE: ABT) by 12.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,567 shares of the healthcare product maker's stock after selling 5,008 shares during the period. Banco
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) is up 9.39% YTD in 2026, decisively outperforming SPY's 1.08%. Dividend Aristocrats are regaining momentum after a weak 2025, with 55 outpacing SPY and 39 posting double-digit gains this year already. Dividend growth is lagging, with 2026's average increase currently at 3.22%, below last year's trend and potentially signaling headwinds.
Aster Capital Management DIFC Ltd acquired a new position in shares of Abbott Laboratories (NYSE: ABT) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 21,796 shares of the healthcare product maker's stock, valued at approximately $2,919,000. Abbott Laboratories comprises about 1.5% of
DNB Asset Management AS reduced its position in Abbott Laboratories (NYSE: ABT) by 6.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 464,128 shares of the healthcare product maker's stock after selling 34,333 shares during the period. DNB
Andra AP fonden purchased a new stake in Abbott Laboratories (NYSE: ABT) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 318,908 shares of the healthcare product maker's stock, valued at approximately $42,715,000. Several other hedge funds and other institutional investors
Both ISRG and ABT closed 2025 on a strong note, but Intuitive Surgical's surging procedure growth and innovation may give it the edge for long-term gains.
Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects
Abbott Labs has raised its dividends for 54 consecutive years. The company expects earnings growth from its acquisition of Exact Sciences.
Abbott (ABT) reached $115.29 at the closing of the latest trading day, reflecting a +2.74% change compared to its last close.
Abbott Laboratories' business, if not exciting, is resilient and consistent. The company is a leader in multiple markets and has attractive growth avenues.
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alliance Wealth Advisors LLC UT lowered its stake in Abbott Laboratories (NYSE: ABT) by 30.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,225 shares of the healthcare product maker's stock after selling 8,086 shares during the quarter. Alliance
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie.
ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case.
Elefante Mark B boosted its position in shares of Abbott Laboratories (NYSE: ABT) by 12.7% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 43,648 shares of the healthcare product maker's stock after purchasing an additional 4,910 shares during the quarter. Abbott Laboratories
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
LISTING LINK: https://www.premiersothebysrealty.com/single-family/mfr/a4681242/6610-gulf-of-mexico-drive-longboat-key-fl-34228 DROPBOX: https://tours.coastalhomephotography.net/public/vtour/display/2359971?idx=1#!/nav/gallery PHOTO CREDIT: Coastal Home Photography LONGBOAT KEY, Fla.